Skip to main content
. 2020 Jan 10;133(5):jcs238030. doi: 10.1242/jcs.238030

Fig. 6.

Fig. 6. Pharmacokinetics data of K161 levels in blood and brain from BL6 mice. (A,B) Mass spectrometry quantification of K161 levels in either the blood plasma (A; [ng/ml]) or the cerebral cortex (B [ng/cortex]) calculated as ng of K161 in the total cortex, after i.p. injection or oral gavage of the inhibitor. Blood was harvested and the concentration of K161 measured at times after treatment with K161 as indicated in A (n=6/group) or 48 h after treatment with K161 for cerebral cortex samples in B (n=3/group). Error bars indicate the s.e.m. (A), min to max (B).

Pharmacokinetics data of K161 levels in blood and brain from BL6 mice. (A,B) Mass spectrometry quantification of K161 levels in either the blood plasma (A; [ng/ml]) or the cerebral cortex (B [ng/cortex]) calculated as ng of K161 in the total cortex, after i.p. injection or oral gavage of the inhibitor. Blood was harvested and the concentration of K161 measured at times after treatment with K161 as indicated in A (n=6/group) or 48 h after treatment with K161 for cerebral cortex samples in B (n=3/group). Error bars indicate the s.e.m. (A), min to max (B).